Liquidia Corporation reported $451M of revenue over the trailing twelve months, +2234% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $451M (to Q2 2026). Net income: $139M, trailing twelve months to Q2 2026. Free cash flow: $151M, trailing twelve months to Q2 2026. Operating margin: 30%, trailing twelve months to Q2 2026.

LQDALiquidia Corporation

Healthcare

$27.39+15% 1Y

$27.39

$21.8052 weeks$91.06

LQDA as reported

Liquidia Corporation reported $451M of revenue over the trailing twelve months, +2234% on the year before. 10 reported series are charted on this page, each one as filed.

$451M

Revenue, trailing twelve months · to Q2 2026 · +2234% against the twelve months before

Net income: $139M
Net income · −193% year on year · trailing twelve months to Q2 2026
Free cash flow: $151M
Free cash flow · −225% year on year · trailing twelve months to Q2 2026
Operating margin: 30%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for LQDA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$451M	+2234%	Q2 2026
Net income	$139M	−193%	Q2 2026
EPS	$1.39	−178%	Q2 2026
Gross margin	57%	n/a	Q1 2025 · 5 quarters behind
Operating margin	30%	n/a	Q2 2026
Net margin	23%	n/a	Q2 2026
ROE	−154%	n/a	Q2 2026
ROA	−8.3%	n/a	Q2 2026
ROIC	−189%	n/a	Q4 2022 · 14 quarters behind
Free cash flow	$151M	−225%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.